Xiaohua WU
M.D., PhD
E-mail: wu.xh@fudan.edu.cn
 

Professor Xiaohua Wu finished doctoral fellow at Shanghai Medical University, and postdoctoral fellow at the New Jersey Cancer Institute, is MD, Ph.D., Chief physician, professor and PhD., supervisor of Oncology of Fudan University Shanghai Cancer Center, Shanghai, China. As the chairman and chief expert of the multidisciplinary team in Gynecologic Oncology, he dedicated in both clinical, and fundamental research for decades, mainly engaged in molecular oncobiological mechanisms for gynecologic malignancies, and conducted pre-clinical and clinical project organizations and research at the level of gene, protein, cell, animal and clinical practice. He has presided or participated in over more than 20 clinical trials at domestic and abroad, including pivotal clinical trials, which promoted the development of targeted treatment for the benefit of patients. In translational studies, he led large-scale and multi-centre research for seeking the status of BRCA gene mutations in Chinese female patients with high-grade serus ovarian carcinoma. Also, he established a "full-scale management model for diagnosis and treatment in ovarian carcinoma", including genetic counselling, preoperative evaluation and postoperative follow-up and also clinical research for individualized management.  He, along with his team, also established the "Fudan Criteria" for abdominal radical trachelectomy (ART) based on the most cases of radical trachelectomy surgery accumulated for young cervical cancer patients who desired to preserve fertility. His research innovated and optimized the critical technology of ART surgery, with 12 patents related to ART surgery was also recommended by the NCCN (National Comprehensive Cancer Network) guideline for cervical and endometrial carcinoma. He has published more than 100 SCI articles in Annals of Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer , BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Gynecologic Oncology, European Journal of Cancer, Journal of Gynecologic Oncology, etc. He served as the member of the editorial board of Cancer Medicine, Journal of Gynecologic Oncology, International Journal of Gynecological Cancer, Chinese Journal of Gynecology and Obstetrics, Chinese Journal of Clinical Anatomy, etc. He presided or participated in over a number of national natural resources funds and served as the research backbone of a large number of significant research projects of the Ministry of Science and Technology. He also served as the President of Chinese Gynecological Cancer Society (CGCS), Chinese Anti-cancer Association (CACA), and the designated member of Council of Chinese Society of Clinical Oncology (CSCO), Education Committee of IGCS (International Gynecologic Cancer Society), International Committee of SGO (Society of Gynecological Oncologists), etc. He was assigned as the adjunct professor of Northwestern University, Feinberg School of Medicine, Department of Obstetrics and Gynecology, USA. Professor Wu achieved the title of Outstanding academic leaders in Shanghai and Leading medical talents in Shanghai. He also won the first prize of Shanghai Anti-Cancer Association, the third prize of Chinese Medical Science and Technology Award.


Research Focus:

• Research on molecular biomarkers related to genetic susceptibility and targeted therapy for ovarian carcinoma; p53 mutation in ovarian cancer and the targeted clinical medication; mechanism of PARPi resistance and sensitizers;

• 
Sensitivity and mechanism of neoadjuvant chemotherapy for advanced ovarian cancer; comparison of preoperative endoscopic evaluation methods for advanced ovarian cancer in the decision-making of surgical methods, and selection of postoperative consolidation and maintenance treatment;

• 
The comparison of different surgical methods on the fertility-preserving function of cervical cancer and the operational mode after neoadjuvant chemotherapy.

• 
Research on radiotherapy resistance in cervical cancer, and the sensitization mechanism, risk factors of lymphatic metastasis and clinical biomarkers.